An IDTechEx Research report titled “Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027”, predicts biosensors for point-of-care (PoC) testing market will grow to $33 billion by 2027, with molecular diagnostic devices the main driver for this growth. Biosensors are used to detect and quantify biological material associated with a disease state or health condition (biomarkers). Biosensors are therefore powerful tools for diagnosis and monitoring. As technological advances allow for such tests to be conducted faster and on smaller devices, these tests are moving out of specialized laboratories and closer to the patient at the point-of-care. The report gives a complete analysis of the important trends in the field of medical biosensors and lists the new technologies and devices which are likely to be highly disruptive to the in vitro diagnostics market.
Medical biosensors can diagnose a numerous diseases and health conditions, such as diabetes, cardiovascular issues, infectious diseases and cancer. Increasingly, biosensors are also being used to achieve targeted therapies in precision medicine and increase the efficacy of drugs through pharmacogenomics. As this market expands, investing in the right technology and business model is now paramount to success over the next decade. ‘Biosensors for Point-of-Care Testing: Technologies, Applications, Forecasts 2017-2027’ will be of great benefit to any company wishing to be in the value chain of biosensors (materials suppliers, reagent suppliers, microfluidics, contract manufacturers, foundries). More details are available.